These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35212182)

  • 1. Probing the proteome to explore potential correlates of increased Alzheimer's-related cerebrovascular disease in adults with Down syndrome.
    Moni F; Petersen ME; Zhang F; Lao PJ; Zimmerman ME; Gu Y; Gutierrez J; Rizvi B; Laing KK; Igwe KC; Sathishkumar M; Keator D; Andrews H; Krinsky-McHale S; Head E; Lee JH; Lai F; Yassa MA; Rosas HD; Silverman W; Lott IT; Schupf N; O'Bryant S; Brickman AM
    Alzheimers Dement; 2022 Oct; 18(10):1744-1753. PubMed ID: 35212182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer-Related Cerebrovascular Disease in Down Syndrome.
    Lao PJ; Gutierrez J; Keator D; Rizvi B; Banerjee A; Igwe KC; Laing KK; Sathishkumar M; Moni F; Andrews H; Krinsky-McHale S; Head E; Lee JH; Lai F; Yassa MA; Rosas HD; Silverman W; Lott IT; Schupf N; Brickman AM
    Ann Neurol; 2020 Dec; 88(6):1165-1177. PubMed ID: 32944999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obstructive sleep apnea, cerebrovascular disease, and amyloid in older adults with Down syndrome across the Alzheimer's continuum.
    Lao P; Zimmerman ME; Hartley SL; Gutierrez J; Keator D; Igwe KC; Laing KK; Cotton-Samuel D; Sathishkumar M; Moni F; Andrews H; Krinsky-McHale S; Head E; Lee JH; Lai F; Yassa MA; Diana Rosas H; Silverman W; Lott IT; Schupf N; Brickman AM
    Sleep Adv; 2022; 3(1):zpac013. PubMed ID: 35669316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma Total-Tau and Neurofilament Light Chain as Diagnostic Biomarkers of Alzheimer's Disease Dementia and Mild Cognitive Impairment in Adults with Down Syndrome.
    Petersen ME; Rafii MS; Zhang F; Hall J; Julovich D; Ances BM; Schupf N; Krinsky-McHale SJ; Mapstone M; Silverman W; Lott I; Klunk W; Head E; Christian B; Foroud T; Lai F; Diana Rosas H; Zaman S; Wang MC; Tycko B; Lee JH; Handen B; Hartley S; Fortea J; O'Bryant S;
    J Alzheimers Dis; 2021; 79(2):671-681. PubMed ID: 33337378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrovascular contributions to aging and Alzheimer's disease in Down syndrome.
    Wilcock DM; Schmitt FA; Head E
    Biochim Biophys Acta; 2016 May; 1862(5):909-14. PubMed ID: 26593849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer's disease-related inhibitory circuit dysfunction in adults with Down syndrome.
    Belbin O; Xiao MF; Xu D; Carmona-Iragui M; Pegueroles J; Benejam B; Videla L; Fernández S; Barroeta I; Nuñez-Llaves R; Montal V; Vilaplana E; Altuna M; Clarimón J; Alcolea D; Blesa R; Lleó A; Worley PF; Fortea J
    Mol Neurodegener; 2020 Aug; 15(1):46. PubMed ID: 32807227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study.
    Fagan AM; Henson RL; Li Y; Boerwinkle AH; Xiong C; Bateman RJ; Goate A; Ances BM; Doran E; Christian BT; Lai F; Rosas HD; Schupf N; Krinsky-McHale S; Silverman W; Lee JH; Klunk WE; Handen BL; Allegri RF; Chhatwal JP; Day GS; Graff-Radford NR; Jucker M; Levin J; Martins RN; Masters CL; Mori H; Mummery CJ; Niimi Y; Ringman JM; Salloway S; Schofield PR; Shoji M; Lott IT; ;
    Lancet Neurol; 2021 Aug; 20(8):615-626. PubMed ID: 34302786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
    Fortea J; Vilaplana E; Carmona-Iragui M; Benejam B; Videla L; Barroeta I; Fernández S; Altuna M; Pegueroles J; Montal V; Valldeneu S; Giménez S; González-Ortiz S; Muñoz L; Estellés T; Illán-Gala I; Belbin O; Camacho V; Wilson LR; Annus T; Osorio RS; Videla S; Lehmann S; Holland AJ; Alcolea D; Clarimón J; Zaman SH; Blesa R; Lleó A
    Lancet; 2020 Jun; 395(10242):1988-1997. PubMed ID: 32593336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome.
    Lleó A; Carmona-Iragui M; Videla L; Fernández S; Benejam B; Pegueroles J; Barroeta I; Altuna M; Valldeneu S; Xiao MF; Xu D; Núñez-Llaves R; Querol-Vilaseca M; Sirisi S; Bejanin A; Iulita MF; Clarimón J; Blesa R; Worley P; Alcolea D; Fortea J; Belbin O
    Alzheimers Res Ther; 2021 Jun; 13(1):119. PubMed ID: 34183050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study.
    Boerwinkle AH; Gordon BA; Wisch J; Flores S; Henson RL; Butt OH; McKay N; Chen CD; Benzinger TLS; Fagan AM; Handen BL; Christian BT; Head E; Mapstone M; Rafii MS; O'Bryant S; Lai F; Rosas HD; Lee JH; Silverman W; Brickman AM; Chhatwal JP; Cruchaga C; Perrin RJ; Xiong C; Hassenstab J; McDade E; Bateman RJ; Ances BM; ;
    Lancet Neurol; 2023 Jan; 22(1):55-65. PubMed ID: 36517172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal telomere shortening and early Alzheimer's disease progression in adults with down syndrome.
    Jenkins EC; Marchi EJ; Velinov MT; Ye L; Krinsky-McHale SJ; Zigman WB; Schupf N; Silverman WP
    Am J Med Genet B Neuropsychiatr Genet; 2017 Dec; 174(8):772-778. PubMed ID: 28856789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multimodal brain age estimates relate to Alzheimer disease biomarkers and cognition in early stages: a cross-sectional observational study.
    Millar PR; Gordon BA; Luckett PH; Benzinger TLS; Cruchaga C; Fagan AM; Hassenstab JJ; Perrin RJ; Schindler SE; Allegri RF; Day GS; Farlow MR; Mori H; Nübling G; ; Bateman RJ; Morris JC; Ances BM
    Elife; 2023 Jan; 12():. PubMed ID: 36607335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET Imaging of Tau Pathology and Relationship to Amyloid, Longitudinal MRI, and Cognitive Change in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI).
    Rafii MS; Lukic AS; Andrews RD; Brewer J; Rissman RA; Strother SC; Wernick MN; Pennington C; Mobley WC; Ness S; Matthews DC;
    J Alzheimers Dis; 2017; 60(2):439-450. PubMed ID: 28946567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective Impairment of Long-Range Default Mode Network Functional Connectivity as a Biomarker for Preclinical Alzheimer's Disease in People with Down Syndrome.
    DiProspero ND; Keator DB; Phelan M; van Erp TGM; Doran E; Powell DK; Van Pelt KL; Schmitt FA; Head E; Lott IT; Yassa MA
    J Alzheimers Dis; 2022; 85(1):153-165. PubMed ID: 34776436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developmental deficits and staging of dynamics of age associated Alzheimer's disease neurodegeneration and neuronal loss in subjects with Down syndrome.
    Wegiel J; Flory M; Kuchna I; Nowicki K; Wegiel J; Ma SY; Zhong N; Bobrowicz TW; de Leon M; Lai F; Silverman WP; Wisniewski T
    Acta Neuropathol Commun; 2022 Jan; 10(1):2. PubMed ID: 34983655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microvascular changes in Down syndrome with Alzheimer's-type pathology: Insights into a potential vascular mechanism for Down syndrome and Alzheimer's disease.
    Drachman DA; Smith TW; Alkamachi B; Kane K
    Alzheimers Dement; 2017 Dec; 13(12):1389-1396. PubMed ID: 28627379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gait dyspraxia as a clinical marker of cognitive decline in Down syndrome: A review of theory and proposed mechanisms.
    Anderson-Mooney AJ; Schmitt FA; Head E; Lott IT; Heilman KM
    Brain Cogn; 2016 Apr; 104():48-57. PubMed ID: 26930369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetic resonance imaging, Down's syndrome and Alzheimer's disease: research and clinical implications.
    Prasher V; Cumella S; Natarajan K; Rolfe E; Shah S; Haque MS
    J Intellect Disabil Res; 2003 Feb; 47(Pt 2):90-100. PubMed ID: 12542574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroimaging and other modalities to assess Alzheimer's disease in Down syndrome.
    Neale N; Padilla C; Fonseca LM; Holland T; Zaman S
    Neuroimage Clin; 2018; 17():263-271. PubMed ID: 29159043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The amyloid plaque proteome in early onset Alzheimer's disease and Down syndrome.
    Drummond E; Kavanagh T; Pires G; Marta-Ariza M; Kanshin E; Nayak S; Faustin A; Berdah V; Ueberheide B; Wisniewski T
    Acta Neuropathol Commun; 2022 Apr; 10(1):53. PubMed ID: 35418158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.